Fecal Microbiota Transplants Annually and Their Positive Clinical Impact

INTRODUCTION: Although fecal microbiota transplantation (FMT) is a recommended, clinically efficacious, and cost-effective treatment for recurrent Clostridioides difficile infection (CDI), the scale of FMT use in the United States is unknown. METHODS: We developed a population-level CDI model. RESUL...

Descripción completa

Detalles Bibliográficos
Autores principales: Mamoon, Lamia, Olesen, Scott W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594930/
https://www.ncbi.nlm.nih.gov/pubmed/33259159
http://dx.doi.org/10.14309/ctg.0000000000000247
_version_ 1783601728101285888
author Mamoon, Lamia
Olesen, Scott W.
author_facet Mamoon, Lamia
Olesen, Scott W.
author_sort Mamoon, Lamia
collection PubMed
description INTRODUCTION: Although fecal microbiota transplantation (FMT) is a recommended, clinically efficacious, and cost-effective treatment for recurrent Clostridioides difficile infection (CDI), the scale of FMT use in the United States is unknown. METHODS: We developed a population-level CDI model. RESULTS: We estimated that 48,000 FMTs could be performed annually, preventing 32,000 CDI recurrences. DISCUSSION: Improving access to FMT could lead to tens of thousands fewer C. difficile episodes per year.
format Online
Article
Text
id pubmed-7594930
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer
record_format MEDLINE/PubMed
spelling pubmed-75949302020-11-04 Fecal Microbiota Transplants Annually and Their Positive Clinical Impact Mamoon, Lamia Olesen, Scott W. Clin Transl Gastroenterol Article INTRODUCTION: Although fecal microbiota transplantation (FMT) is a recommended, clinically efficacious, and cost-effective treatment for recurrent Clostridioides difficile infection (CDI), the scale of FMT use in the United States is unknown. METHODS: We developed a population-level CDI model. RESULTS: We estimated that 48,000 FMTs could be performed annually, preventing 32,000 CDI recurrences. DISCUSSION: Improving access to FMT could lead to tens of thousands fewer C. difficile episodes per year. Wolters Kluwer 2020-10-27 /pmc/articles/PMC7594930/ /pubmed/33259159 http://dx.doi.org/10.14309/ctg.0000000000000247 Text en © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Mamoon, Lamia
Olesen, Scott W.
Fecal Microbiota Transplants Annually and Their Positive Clinical Impact
title Fecal Microbiota Transplants Annually and Their Positive Clinical Impact
title_full Fecal Microbiota Transplants Annually and Their Positive Clinical Impact
title_fullStr Fecal Microbiota Transplants Annually and Their Positive Clinical Impact
title_full_unstemmed Fecal Microbiota Transplants Annually and Their Positive Clinical Impact
title_short Fecal Microbiota Transplants Annually and Their Positive Clinical Impact
title_sort fecal microbiota transplants annually and their positive clinical impact
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594930/
https://www.ncbi.nlm.nih.gov/pubmed/33259159
http://dx.doi.org/10.14309/ctg.0000000000000247
work_keys_str_mv AT mamoonlamia fecalmicrobiotatransplantsannuallyandtheirpositiveclinicalimpact
AT olesenscottw fecalmicrobiotatransplantsannuallyandtheirpositiveclinicalimpact

Ejemplares similares